Poster Abstracts
Grand Hall CD (Manchester Grand Hyatt)
Single Center Experience with High Dose Melphalan and Two Day Washout in Patients with Multiple Myeloma on Hemodialysis Undergoing Autologous Stem Cell Transplant
Mona Lisa Alattar, MD, University of Texas Southwestern Medical Center;
Prapti Patel, MD, University of Texas Southwestern Medical Center;
LD Anderson Jr., MD, PhD, University of Texas Southwestern Medical Center;
Robert H. Collins, MD, UTSW Medical Center;
Song Zhang, PhD, University of Texas Southwestern Medical Center;
Harris Naina, MD, University of Texas Southwestern Medical Center;
Chi Yin Kwong, PharmD, University of Texas Southwestern Medical Center;
Madhuri Vusirikala, MD, University of Texas Southwestern Medical Center
First Report on an Ongoing Pilot Clinical Study Incorporating Hyperbaric Oxygen into Autologous Peripheral Blood Stem Cell Transplantation
Omar Aljitawi, MD, University of Kansas Medical Center;
Siddhartha Ganguly, MD, FACP, University of Kansas Medical Center;
Tara L. Lin, MD, Unviersity of Kansas Medical Center;
Jonathan Mahnken, PhD, University of Kansas Medical Center;
Shana L. Palla, University of Kansas Medical Center;
Jennifer Bunch, University of Kansas Medical Center;
Stacy Supancic, University of Kansas Medical Center;
Anurag K Singh, MD, University Of Kansas Medical Center;
Leyla Shune, MD, University of Kansas Medical Center;
Sunil Abhyankar, MD, University of Kansas Medical Center;
Dennis Allin, MD, University of Kansas Medical Center;
Joseph McGuirk, DO, University of Kansas Medical Center
Poor Peripheral Blood Stem Cell Mobilization Correlates with Worse Long-Term Outcomes in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Jan S. Moreb, MD, University of Florida;
Ayed O Ayed, MD, University of Florida;
Michael Byrne, MD, Helen Diller Comprehensive Cancer Center, University of California;
Ilicia Shugarman, MD, University of Florida;
Dai Yunfeng, Graduate student, University of Florida;
Myron Chang, PhD, University of Florida;
Maxim Norkin, MD, University of Florida;
John Hiemenz, MD, University of Florida;
Randall Brown, MD, University of Florida;
Christopher Ramin Cogle, MD, University of Florida;
William S May, University of Florida;
John R. Wingard, MD, University of Florida;
Jack W. Hsu, MD, University of Florida
Cyclophosphamide Dose Weight Adjustment in Morbidly Obese with Lymphoma Is Safe and Yields Favorable Outcomes after Autologous Hematopoietic Cell Transplantation (HCT)
Veronika Bachanova, MD, University of Minnesota Medical Center;
John Rogosheske, PharmD, University of Minnesota Medical Center, Fairview;
Ryan Shanley, M.S., University of Minnesota Medical Center;
Linda J. Burns, MD, National Marrow Donor Program;
Daniel J. Weisdorf, MD, University of Minnesota Medical Center;
Claudio G. Brunstein, MD, PhD, University of Minnesota Medical Center
Outcome of Patients with Systemic Light Chain (AL) Amyloidosis with Concurrent Renal and Cardiac Involvement
Talha Badar, MBBS, University of Texas MD Anderson Cancer Center;
Simrit Parmar, MD, The University of Texas MD Anderson Cancer Center;
A. Megan Cornelison, MS, PA-C, UT MD Anderson Cancer Center;
Nina Shah, MD, The University of Texas MD Anderson Cancer Center;
Qaiser Bashir, MD, The University of Texas MD Anderson Cancer Center;
Krina Patel, MD, The University of Texas MD Anderson Cancer Center;
Chitra Hosing, MD, The University of Texas MD Anderson Cancer Center;
Uday R. Popat, MD, UT MD Anderson Cancer Center;
Richard E. Champlin, MD, The University of Texas MD Anderson Cancer Center;
Muzaffar H. Qazilbash, MD, The University of Texas MD Anderson Cancer Center
Pretransplant Minimal Residual Disease (MRD) Positivity Independently Predicts Survival in a Unselected Cohort of Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission
Andrew J. Cowan, MD, Fred Hutchinson Cancer Research Center (FHCRC);
Philip A. Stevenson, Fred Hutchinson Cancer Research Center (FHCRC);
Ryan D. Cassaday, MD, University of Washington;
Solomon A. Graf, MD, Fred Hutchinson Cancer Research Center (FHCRC);
Leona Holmberg, MD, PhD, Fred Hutchinson Cancer Research Center (FHCRC);
Jonathan R. Fromm, MD, University of Washington;
Brian G. Till, MD, Fred Hutchinson Cancer Research Center (FHCRC);
David Wu, MD, University of Washington;
Thomas Chauncey, MD, PhD, VA Puget Sound Healthcare System (VAPSHCS);
Stephen D. Smith, MD, Fred Hutchinson Cancer Research Center (FHCRC);
Mary Philip, MD, Fred Hutchinson Cancer Research Center (FHCRC);
Johnnie J. Orozco, MD, PhD, Fred Hutchinson Cancer Research Center;
Andrei R. Shustov, MD, Fred Hutchinson Cancer Research Center (FHCRC);
Damian J Green, MD, Fred Hutchinson Cancer Research Center;
Edward N. Libby, MD, Fred Hutchinson Cancer Research Center (FHCRC);
William Bensinger, MD, Fred Hutchinson Cancer Research Center (FHCRC);
Mazyar Shadman, MD, MPH, University of Washington;
David G. Maloney, MD, PhD, Fred Hutchinson Cancer Research Center;
Oliver W. Press, MD, PhD, Fred Hutchinson Cancer Research Ctr/U. Washington;
Ajay K. Gopal, MD, University of Washington School of Medicine
Comparison of Fludarabine, Intravenous Busulfan, and Total Body Irradiation (FluBuTBI) to BEAM As Conditioning Regimens for Autologous Peripheral Blood Stem Cell Transplantation in Non-Hodgkins Lymphoma
Jocelyn De Yao, MD, Allegheny Health Network;
Santhosh Sadashiv, MD, Allegheny Health Network;
Entezam A Sahovic, M.D., Allegheny Health Network;
Sanaullah Khalid, MD, Allegheny Health Network;
Pritam Tayshetye, MD, Allegheny Health Network;
James Rossetti, DO, Allegheny Health Network;
Salman Fazal, MD, Allegheny Health Network;
Gina Berteotti, Allegheny Health Network;
John Lister, M.D., Allegheny Health Network
Bortezomib-Based Induction Therapy PRIOR to High Dose Melphalan and Autologous Hematopoietic CELL Transplantaiton in Primary Amyloidosis
Hien K. Duong, MD, Cleveland Clinic;
Lisa Rybicki, MS, Cleveland Clinic Taussig Cancer Institute;
Donna Abounader, CCRP, Cleveland Clinic;
Brian Bolwell, MD, Cleveland Clinic;
Matt E. Kalaycio, MD, Cleveland Clinic;
Jason Valent, MD, Cleveland Clinic Foundation;
Christy Samaras, MD, Cleveland Clinic Foundation;
Fred Reu, MD, Cleveland Clinic Taussig Cancer Institute;
Ronald Sobecks, MD, Taussig Cancer Institute, Cleveland Clinic;
Deepa Jagadeesh, MD, MPH, Umass Medical School;
Betty Hamilton, Cleveland Clinic;
Steven Andresen, DO, Cleveland Clinic;
Aaron Gerds, MD, Cleveland Clinic;
Rabi Hanna, MD, Cleveland Clinic;
Brad Pohlman, MD, Cleveland Clinic;
Navneet S. Majhail, MD, MS, Cleveland Clinic
Tbo-Filgrastim Versus Filgrastim during Mobilization and Neutrophil Engraftment in Autologous Stem Cell Transplantation
Mohammed M. Elayan, PharmD, Texas Transplant Institute;
Jose M. Magraner, Texas Transplant Institute;
Justin G. Horowitz, Texas Transplant Institute;
Candace Taylor, CCRP, Texas Transplant Institute;
Penny McGavran, Texas Transplant Institute;
Paul J. Shaughnessy, MD, Texas Transplant Institute;
Carlos Bachier, MD, Texas Transplant Institute
Cerebral Venous Thrombosis after Autologous Stem Cell Transplantation
Hermina D Fernandes, MD, Saint Louis University;
Dhivya Sugumar, MD, St.Mary's Health Center;
Mark Fesler, MD, Saint Louis University;
Sagun D Goyal, MD, MSc, Saint Louis University;
Jack Lionberger, MD, PhD, St.Louis University
In Vivo Purging May Not be Required in the Era of Universal Use of Rituximab Containing Chemo-Immunotherapy in Patients with Follicular and Mantle Cell Lymphoma: A Single Center Experience
Anurag K Singh, MD, University Of Kansas Medical Center;
Clint L. Divine, MBA, MSM, University of Kansas Cancer Center;
Omar Aljitawi, MD, University of Kansas Medical Center;
Sunil Abhyankar, MD, University of Kansas Medical Center;
Joseph P McGuirk, DO, University of Kansas Med Ctr MS 5003;
Siddhartha Ganguly, MD, FACP, University of Kansas Medical Center
The Addition of Meloxicam to G-CSF Is Associated with Good Mobilization Rates, Faster Engraftment and Reduced Toxicity and Hospital Stay after Autologous Stem Cell Transplantation – a Phase II Study
Biju George, MD, Christian Medical College;
Auro Viswabandya, MD, Christian Medical College;
Ansu Anbu Alex, Christian Medical College;
Kavitha Lakshmi, MSc, Christian Medical College;
Aby Abraham, MD, Christian Medical College;
Abhijeet Ganapule, MD, Christian Medical College;
Fouzia N A, Christian Medical College;
Alok Srivastava, MD, Christian Medical College;
Vikram Mathews, MD, Christian Medical College
Predictors of Survival in Multiple Myeloma Patients after Relapse from a Delayed Autologous Stem Cell Transplant
Wilson I Gonsalves, MD, Mayo Clinic;
Morie Gertz, MD, Mayo Clinic;
Angela Dispenzieri, MD, Mayo Clinic;
Martha Lacy, MD, Mayo Clinic;
Francis Buadi, MD, Mayo Clinic;
David Dingli, MD, Mayo Clinic;
Suzanne Hayman, MD, Mayo Clinic;
Prashant Kapoor, MD, Mayo Clinic;
S. Vincent Rajkumar, Mayo Clinic;
Shaji Kumar, MD, Mayo Clinic
Results of a Phase II Study of Propylene Glycol (PG)-Free, Captisol-Enabled Melphalan Conditioning for Autologous Hematopoietic Stem Cell Transplantation (AHCT) in Patients with Multiple Myeloma (MM)
Parameswaran N. Hari, MD, MS, CIBMTR/Medical College of Wisconsin;
Omar Ajitawi, MD, KU Medical Center;
Carlos Arce-Lara, MD, Medical College of Wisconsin;
Rajneesh Nath, MD, University of Massachusetts;
Natalie Callander, MD, University of Wisconsin Hospital and Clinics;
Gajanan Bhat, PhD, Spectrum Pharmaceuticals;
Lee F. Allen, MD, PhD, Spectrum Pharmaceuticals;
Keith Stockerl-Goldstein, MD, Washington University School of Medicine
Cytomegalovirus (CMV) Infection in Autologous Stem Cell Transplant (ASCT) Recipients in the Era of Rituximab (R) Use
Tania Jain, MD, Wayne State University/ Detroit Medical Center;
Jisha John, MD, Wayne State University;
Aditya Kotecha, MBBS, Wayne State University;
Sanjay Revankar, MD, Karmanos Cancer Institute;
Pranatharthi Chandrasekar, MD, Karmanos Cancer Institute
Outcomes of Autologous Stem Cell Transplant (ASCT) in African-American (AA) Patients with Multiple Myeloma (MM)
Tania Jain, MD, Wayne State University/ Detroit Medical Center;
Maria Diab, Wayne State University/ Detroit Medical Center;
Reda Awali, Wayne State University;
Joseph Uberti, MD, Karmanos Cancer Institute/ Wayne State University;
Voravit Ratanatharathorn, MD, Karmanos Cancer Institute/ Wayne State University;
Lois Jeanne Ayash, MD, Karmanos Cancer Institute/ Wayne State University;
Abhinav Deol, MD, Karmanos Cancer Institute/ Wayne State University;
Divaya Bhutani, MD, Karmanos Cancer Institute/ Wayne State University;
Muneer H. Abidi, MD, Karmanos Cancer Institute/ Wayne State University
CXCR4 Expression in Mantle Cell Lymphoma and Mobilization with Plerixafor for ASCT Does Not Negatively Impact Progression-Free Survival
Hidong Kim, MD, PhD, Mayo Clinic;
Patrick B Johnston, MD, PhD, Mayo Clinic;
Betsy LaPlant, Mayo Clinic;
Stephen Ansell, MD, PhD, Mayo Clinic;
David J Inwards, MD, Mayo Clinic;
Luis F Porrata, MD, Mayo Clinic;
Ivana N Micallef, MD, Mayo Clinic
Long-Term Outcomes of 133 Patients with Intermediate-Risk Acute Myeloid Leukemia Treated with High-Dose Chemotherapy and Autologous Stem Cell Rescue in First Complete Remission
Gabriel N. Mannis, MD, University of California San Francisco;
Thomas G. Martin, MD, University of California San Francisco;
Lloyd E Damon, MD, University of California San Francisco;
Aaron C. Logan, University of California San Francisco;
Weiyun Ai, MD, PhD, University of California San Francisco;
Karin ML Gaensler, MD, University of California San Francisco;
Lawrence D Kaplan, MD, University of California San Francisco;
Anuj Mahindra, MD, University of California San Francisco;
Rebecca L. Olin, MD, MSCE, University of California San Francisco;
Peter Sayre, MD, University of California San Francisco;
Catherine C Smith, MD, University of California San Francisco;
Jeffrey L. Wolf, MD, University of California San Francisco;
Jimmy Hwang, PhD, University of California San Francisco;
Charalambos Andreadis, MD, MSCE, University of California San Francisco
Severe Mucositis with Bendamustine Etoposide Ara-C and Melphalan (Be-EAM) As Conditioning Regimen in Non-Hodgkin Lymphoma (NHL) Patients Undergoing Autologous Stem Cell Transplantation (AutoSCT)
Antonio M Jimenez, MD, Rush University Medical Center;
Sunita Nathan, MD, Rush University Medical Center;
Alfonso D Moreno, Rush University Medical Center;
John Maciejewski, MD, PhD, Rush University Medical Center;
Henry C Fung, MD, Temple University Hospital/Fox Chase Cancer Center
Pegfilgrastim and Planned Plerixafor for Autologous Stem Cell Mobilization Is Safer Than and As Effective As Chemo-Mobilization in Patients with Hematological Malignancies
Manish Sharma, MD, Thomas Jefferson University;
Sherilyn Tuazon, MD, Thomas Jefferson University;
Tingting Zhan, Ph.D., Thomas jefferson University;
John Wagner, MD, Thomas Jefferson University;
Margaret Kasner, MD, Thomas Jefferson University;
Onder Alpdogan, MD, Thomas Jefferson University;
Ubaldo Martinez, MD, Kimmel Cancer Center, Thomas Jefferson University;
Dolores Grosso, DNP, Thomas Jefferson University;
Joanne Filicko, MD, Thomas Jefferson University Hospital;
Thomas Klumpp, MD, Thomas Jefferson University Hospital;
Barbara Pro, MD, Thomas Jefferson University;
Matthew Carabasi, MD, Thomas Jefferson University;
Neal Flomenberg, MD, Thomas Jefferson University;
Mark Weiss, MD, Thomas Jefferson University
Pre-Transplant Serum Biomarkers Predict Early Relapse in Classical Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation
Bryan Trottier, MD, University of Minnesota;
Holly Miller, MD, University of Michigan;
Qing Cao, MS, University of Minnesota;
Jeffrey S. Miller, MD, University of Minnesota;
Michael R. Verneris, MD, University of Minnesota Medical Center, Fairview;
Daniel J. Weisdorf, MD, University of Minnesota Medical Center;
John Levine, MD, MS, University of Michigan;
Linda J. Burns, MD, National Marrow Donor Program
Comparison of Engraftment Syndrome with G-CSF Versus GM-CSF after Autologous Hematopoietic Progenitor Cell Transplantation for Multiple Myeloma
Sherilyn Tuazon, MD, Thomas Jefferson University;
Constantine Daskalakis, ScD, Thomas Jefferson University;
Ashok Mandala, MD, Thomas Jefferson University;
Neeraj Saini, MD, Thomas Jefferson University;
William J. O'Hara, PharmD, Thomas Jefferson Hospital;
Onder Alpdogan, MD, Thomas Jefferson University;
Matthew Carabasi, MD, Thomas Jefferson University;
Joanne Filicko-O'Hara, MD, Thomas Jefferson University;
Neal Flomenberg, MD, Thomas Jefferson University;
Dolores Grosso, DNP, Thomas Jefferson University;
Margaret Kasner, MD, Thomas Jefferson University;
Thomas Klumpp, MD, Thomas Jefferson University Hospital;
Ubaldo Martinez-Outschoorn, MD, Thomas Jefferson University;
Manish Sharma, MD, Thomas Jefferson University;
Mark Weiss, MD, Thomas Jefferson University;
John Wagner, MD, Thomas Jefferson University
![[Visit Client Website]](images/banner.gif)